VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.
Sector: In Vitro & In Vivo Diagnostic Substances
Industry: Medical - Devices
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 30.06M shares outstanding
USVolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia.
The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes.
It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.
Cameron Reynolds
Founder, Chief Executive Officer, President & Director
Dr. Alan Colman
Dr. Alan Colman(3)
Director
Dr. Ethel Rubin
Employees
57
Country
US
Sector
Healthcare
Website
volition.com
Loading congressional disclosures…
based on 30.06M shares outstanding
US30d Avg
3.37M
60d Avg
12.79M
90d Avg
8.62M
